Patient Demographics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>DC Bead (n=102)</th>
<th>cTACE (n=110)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Mean (±sd)</td>
<td>67.0 years (±9.2)</td>
<td>67.3 years (±8.8)</td>
</tr>
<tr>
<td>Sex (Male/Female)</td>
<td>88/14</td>
<td>97/13</td>
</tr>
<tr>
<td>Aetiology (HepC/HepB/Alcohol Alone/Other &amp; Mixed)</td>
<td>20/14/41/27</td>
<td>12/13/52/33</td>
</tr>
</tbody>
</table>

Bilobar disease: both lobes treated within a 3-week period
Microcatheter could be used

Follow-up period: 6 months

DC Bead® is not currently available for sale or distribution and BeadBlock are trademarks of Biocompatibles UK Ltd.
DC Bead is a registered trademark and PRECISION TACE is trademarked by Biocompatibles UK Ltd.

DC Bead® Ordering Information

<table>
<thead>
<tr>
<th>Product Code</th>
<th>100 - 300 µm</th>
<th>300 - 500 µm</th>
<th>500 - 700 µm</th>
</tr>
</thead>
<tbody>
<tr>
<td>DC2V103</td>
<td>2ml</td>
<td>2ml</td>
<td>2ml</td>
</tr>
<tr>
<td>DC2V305</td>
<td>2ml</td>
<td>2ml</td>
<td>2ml</td>
</tr>
<tr>
<td>DC2V507</td>
<td>2ml</td>
<td>2ml</td>
<td>2ml</td>
</tr>
</tbody>
</table>
DC Bead® is a Drug Delivery Embolisation System capable of loading and releasing in a controlled manner high doses of chemotherapeutic agents.¹

**DC Bead Indication for Use**
DC Bead is CE-Mark approved and is intended to be loaded with doxorubicin for the purpose of:
- Embolisation of vessels supplying malignant hypervascularised tumour(s)
- Delivery of a local, controlled, sustained dose of doxorubicin to the tumour(s)
- Embolisation of vessels supplying malignant hypervascularised tumour(s)
- Delivery of high doses of chemotherapeutic agents.¹

**Interaction of Doxorubicin With DC Bead Sulphonate Groups**

**DC Bead Presentation**
- Novel N-R technology sulphonate modified hydrogel polymer
- Blue tinted to aid visualisation
- Delivered as vials containing 2ml Beads in 6ml saline
- Precise calibration to achieve an accurate level of embolisation

**Systemic Exposure – Peak Concentration (Cmax)**

**Doxorubicin-Related Side Effects**

**Response and Adverse Events – Advanced Disease**

**Liver Enzyme Levels (AST)**

**Liver Enzyme Levels (ALT)**

**DC Bead® was shown by Varela et al to deliver a more targeted release of doxorubicin to the tumour(s) with greater consistency. Patients experienced a substantial reduction in both peak concentration and total systemic exposure to doxorubicin.**

**In the PRECISION V clinical trial, patients who received PRECISION TACE with DC Bead® had a highly significant (p=0.001) reduction in doxorubicin-related systemic adverse events, despite receiving 30% more doxorubicin.**

**We believe that these results show that DC Bead® is a better treatment than conventional TACE. An improved response with significantly lower toxicity is unusual for a new cancer therapy.**

**PRECION V Publication Committee**

**“We believe that these results show that DC Bead® is a better treatment than conventional TACE. An improved response with significantly lower toxicity is unusual for a new cancer therapy.”**

**PRECION V Conclusions**
- PRECISION TACE® with DC Bead® is safe, efficacious and reproducible
- There is a highly significant reduction in liver toxicity in PRECISION TACE with DC Bead®
- There is a significant advantage of PRECISION TACE with DC Bead® in more advanced patients – those with more compromised liver function, poorer performance status, bilobar disease and recurrent disease – greater response, greater disease control and improved safety
- Currently AASLD guidelines do not recommend chemoembolisation for CHB B and ECOG 1 patients. The PRECISION V data show that these patients can now be safely treated with PRECISION TACE with DC Bead®